|
BIOGRAPHICAL SKETCHES
COURSE DIRECTORS
Ellen
Frank, PhD
Distinguished Professor of Psychiatry and Professor of Psychology
University of Pittsburgh School of Medicine
Director, Depression and Manic Depression Prevention Program
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Ellen Frank, Ph.D. is
Distinguished Professor of Psychiatry and Professor of Psychology at the
University of Pittsburgh School of Medicine and Director of the
Depression and Manic Depression Prevention program at Western
Psychiatric Institute and Clinic.
Under a MERIT award from the
National Institute of Mental Health (NIMH) Dr. Frank and her colleagues
developed a new psychotherapy—interpersonal and social rhythm therapy
(IPSRT) —for the treatment of manic-depressive illness that has been
implemented across the US and around the world IPSRT has now been
adapted for both group and individual treatment of both bipolar and
unipolar disorders. She recently completed a study with researchers at
the University of Pisa, Italy, aimed at achieving a better understanding
of the clinical importance of subsyndromal mood and anxiety conditions
and their impact on the outcome of treatments for depression.
An expert in mood disorders
and their treatment, Dr. Frank has served as Chair of the Food and Drug
Administration Psychopharmacologic Drugs Advisory Panel and as a member
of the U.S. National Advisory Mental Health Council. She currently
serves on the Mood Disorders Workgroup of the American Psychiatric
Association Task Force on DSM-5 and is an Honorary Fellow of the
American Psychiatric Association. In 1999, Dr. Frank was elected to the
National Academy of Sciences Institute of Medicine.
A prolific writer, Dr. Frank
has published over 390 peer-reviewed papers and more than 100 books and
book chapters.
Dr. Frank graduated from
Vassar College, earned a master’s degree in English at Carnegie Mellon
University and her doctorate in psychology at the University of
Pittsburgh.
Samuel Gershon,
MD
Vice Chairman, Academic Affairs, Department of Psychiatry, University of
Miami, Miami, Florida
Emeritus Professor of Psychiatry, University of Pittsburgh School of
Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Dr. Samuel Gershon joined the faculty at the University of Pittsburgh in
April 1988, as Associate Vice Chancellor for Research in the Health
Sciences, and Associate Research Director for the Neurosciences in the
Department of Psychiatry. He stepped down from this position in 1995 and
assumed the position of Chairman of the Institutional Review Board,
University of Pittsburgh. Prior to his tenure with the University of
Pittsburgh, Dr. Gershon was Director of the Neuropsychopharmacology
Research Unit at New York University for 16 years. He then assumed the
position of Professor and Chairman of the Department of Psychiatry at
Wayne State University and was also the Director of the Lafayette
Clinic. He was a longtime recipient of NIH Research Support during his
years as an investigator.
Dr. Gershon’s career as a psychiatrist and investigator spans more than
50 years. During this time he has published more than 600 writings and
has won several prestigious awards including, among others, the Pfizer
Scholarship for Medical Research Overseas, the American Psychiatric
Association’s Rush Gold Medal Award, the 6th ICBD Mogens Schou Award for
Distinguished Service, and in 2008 the CINP Pioneer Award in
Neuropsychopharmacology. His area of specific interest and work
encompasses psychopharmacological interest in various psychiatric areas.
He is currently the Co-Editor of Bipolar Disorders – An International
Journal of Psychiatry and Neurosciences and has been since its inception
in 1998. He is also a founding Councilor of the International Society
for Bipolar Disorders and served as President from 2001-2005. He is
currently at the Department of Psychiatry, University of Miami.
David J. Kupfer, MD
Thomas Detre Professor, Department of Psychiatry, University of
Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA
David J. Kupfer, M.D., is the Thomas
Detre Professor of the Department of Psychiatry at the University of
Pittsburgh School of Medicine. He is also a Professor of Neuroscience at
the University of Pittsburgh School of Medicine. His previous
appointments include Chairman of the Department of Psychiatry of the
University of Pittsburgh School of Medicine (1983-2009), Medical
Director of Western Psychiatric Institute and Clinic (2001-2009),
positions at Yale University, Griffin Hospital, New Fairview Hall
Convalescent Hospital and the National Institute of Mental Health.
Academically, Dr. Kupfer received his bachelor’s (magna cum laude) and
M.D. degrees from Yale University. Following completion of an
internship, Dr. Kupfer continued his postgraduate clinical and research
training at the Yale New Haven Hospital and at the National Institute of
Mental Health (NIMH). In 1970, he was appointed an assistant professor
of psychiatry at Yale University School of Medicine. Dr. Kupfer joined
the faculty at the University of Pittsburgh in 1973 as an associate
professor of psychiatry and director of research and research training
at Western Psychiatric Institute and Clinic. He was promoted to
professor of psychiatry in 1975 and became Chairman of the department in
1983. He promoted widespread collaborations between clinical
investigators in psychiatry and those in more basic neurosciences. Under
Dr. Kupfer’s direction, WPIC has become one of the nation’s preeminent
university-based psychiatric centers as evidenced by the quality and
number of publications as well as the amount of peer-reviewed federal
funding for mental health research. He has written more than 1000
articles, books, and book chapters that examine treatment in recurrent
depression, the causes of depression, and the relationship between
biomarkers and depression.
In recognition of his contributions to
the field, Dr. Kupfer has been the recipient of numerous awards and
honors including the A.E. Bennett Research Award in Clinical Science
(1975), the Anna-Monika Foundation Prize (1977), the Daniel H. Efron
Award (1979), the Twenty-Sixth Annual Award of the Institute of
Pennsylvania Hospital in Memory of Edward A. Strecker, M.D. (1989), the
William R. McAlpin, Jr, Research Achievement Award (1990), the 1993
American Psychiatric Association Award for Research in Psychiatry, the
First Isaac Ray Decade of Excellence Award (1994), the Twelfth Annual
Edward J. Sachar Award (1996), the 1996 Gerald Klerman Lifetime Research
Award (jointly with Dr. Ellen Frank), the Institute of Medicine’s 1998
Rhoda and Bernard Sarnat International Prize in Mental Health, and the
American Psychopathological Association’s 1999 Joseph Zubin Award
(jointly with Dr. Ellen Frank). He was elected to the Institute of
Medicine of the National Academy of Sciences in 1990. Dr. Kupfer is the
Founding President of the International Society of Bipolar Disorders.
Most recently, he was the 2010 Litchfield lecturer at the Department of
Psychiatry at Oxford University. Dr. Kupfer chairs the American
Psychiatric Association’s Task Force for DSM-5.
Michael E. Thase, MD
Professor of Psychiatry, University of Pennsylvania School of Medicine
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Michael E. Thase, M.D., joined the
faculty of the University of Pennsylvania School of Medicine in January,
2007 as Professor of Psychiatry after more than 27 years at the
University of Pittsburgh Medical Center and the Western Psychiatric
Institute and Clinic. Dr. Thase’s research focuses on the assessment and
treatment of mood disorders, including studies of the differential
therapeutics of both depression and bipolar affective disorder. A 1979
graduate of the Ohio State University College of Medicine, Dr. Thase is
a Distinguished Fellow of the American Psychiatric Association, a
Founding Fellow of the Academy of Cognitive Therapy, a member of the
Board of Directors of the American Society of Clinical
Psychopharmacology, and Vice Chairman of the Scientific Advisory Board
of the National Depression and Bipolar Support Alliance. Dr. Thase has
been elected to the membership of the American College of Psychiatrists
and the American College of Neuropsychopharmacology. Dr. Thase has
authored or co-authored more than 500 scientific articles and book
chapters, as well as 15 books.
FACULTY
Jules Angst, MD
Emeritus Professor of Psychiatry, Zurich University, Zurich, Switzerland
Jules Angst, MD, is Emeritus Professor of
Psychiatry at Zurich University and Honorary Doctor of University of
Heidelberg (Germany). He was Professor of Clinical Psychiatry and Head
of the Research Department of Zurich University Psychiatric Hospital
(the Burghölzli) from 1969 to 1994. Since then he has continued his work
in epidemiological and clinical research at the University.
Memberships: Jules Angst is an Honorary
Fellow of the Royal College of Psychiatrists. He is an Honorary Member
of the Mexican, Chilean, Polish, and Austrian Psychiatric Associations;
the American Psychopathological Association; the German Association of
Biological Psychiatrists, the Swiss Society of Psychiatric Epidemiology;
the Swiss Society of Biological Psychiatry, the European College of
Neuropsychopharmacology and the Association of European Psychiatrists,
of which he was President from 1996 to 1998. In 2002 he was elected
fellow of the American Psychiatric Association.
Awards: Jules Angst has received the Anna
Monika Award (in1967 and in1969), the Paul Martini Prize for Methodology
in Medicine (1969), the Otto Naegeli Prize (1983), the Eric Strömgren
Medal (1987), and the Emil Kraepelin Medal of the Max Planck Institute,
Munich (1992). He has also received the Selo Prize of NARSAD, USA
(1994), the Mogens Schou Award for Research in Bipolar Disorder, USA
(2001), the Burghölzli Award for Social Psychiatry (2001), the Lifetime
Achievement Award of the International Society of Psychiatric Genetics
(2002), the Wagner-Jauregg Medal (2007) and the Juan J. López-Ibor Award
(2010).
David A. Axelson, MD
Associate Professor of Psychiatry, University of Pittsburgh School of
Medicine
Director of the Child and Adolescent Bipolar Services (CABS) Outpatient
Program
Western Psychiatric Institute and Clinic, Pittsburgh, PA
David Axelson, M.D. is an Associate Professor of Psychiatry at the
University of Pittsburgh School of Medicine and the Director of the
Child and Adolescent Bipolar Services (CABS) program at the Western
Psychiatric Institute and Clinic. Dr. Axelson received a B.A. in 1987
from Brown University and his M.D. in 1992 from the Duke University
School of Medicine. He completed a combined General – Child Psychiatry
residency at Western Psychiatric Institute and Clinic in 1997 and a
post-doctoral research fellowship in child and adolescent mood disorders
at the University of Pittsburgh School of Medicine. Dr. Axelson’s
research focuses on the phenomenology, course and treatment of children
and adolescents with bipolar spectrum disorders. He received a career
development award from the National Institute of Mental Health and is
currently a Principal Investigator on a multisite NIMH-funded treatment
study of bipolar youth. He is also a Co-Principal Investigator for
studies examining the phenomenology of pediatric bipolar disorder and
the longitudinal course of the offspring of bipolar parents.
Toni R. Ballard,
MA
Supervisor, Allegheny Family Network, Pittsburgh, PA
Toni Ballard has worked in the Social Work field since 1993, providing
services to families who have children from birth to our more mature
families 60 and over. Toni has held various positions, including those
working with families who have Child Welfare involvement to our families
that work with the Department of Aging on behalf of their love ones.
Toni has provided direct care to families and has held several
management positions throughout her career. Toni received her Bachelor’s
Degree from Lincoln University and her Master’s Degree from Carlow
University. She believes that every family has strengths and she
understands that families generally want the best for their loved ones
and sometimes with a little help can overcome all obstacles.
Currently, she is a credentialed
Coach/Supervisor in High Fidelity Wraparound. She was the first
credentialed Family Support Role Coach in the Country. In her current
position, she supervises Family Support Partners who work in High
Fidelity Wraparound who provide support to families raising children
with MH, Emotional or Behavioral Concerns.
Mark S. Bauer, MD
Professor of Psychiatry, Harvard Medical School
Associate Director, Center for Organization, Leadership, & Management
Research (COLMR)
Boston VA Healthcare System, Boston, MA
Dr. Bauer’s research focus for the last
decade has been on developing, testing, and implementing collaborative
chronic care models to improve evidence-based treatment delivery for
manic-depressive disorder and other serious mental illnesses. He has
pioneered the development of self-management skill enhancement
methodologies for individuals with bipolar disorder through the
portfolio of Life Goals treatments. He has also contributed to research
on the nosology, assessment, and treatment of bipolar disorder
particularly rapid cycling.
Dr. Bauer received his bachelor’s degree
from the University of Chicago and medical degree from the University of
Pennsylvania. He has also served on the faculties of psychiatry and
pharmacology at the University of Pennsylvania and the faculty of
psychiatry at Brown University. He is the author of over 100
peer-reviewed research articles and author or editor of 6 books. He has
won awards for excellence research, teaching, clinical care, and
administration. He has been named Distinguished Fellow of the American
Psychiatric Association and in 2011 received the Klerman Senior
Investigator Award from the Depression and Bipolar Support Alliance.
Michael Berk, MD,
PhD
Chair of Psychiatry for Barwon Health and The Geelong Clinic
University of Melbourne, Melbourne, Australia
Professor Michael Berk is currently appointed as Chair of Psychiatry in
the School of Medicine, Deakin University. He also is a Professorial
Research fellow at the University of Melbourne and the Mental Health
Research Institute, and leads the first episode bipolar program at
Orygen Youth Health. He is immediate past President of the International
Society of Bipolar Disorders, and Chairman of the Australasian Society
of Bipolar Disorders. He has published over 350 papers on a range of
topics with his research interests focusing on mood and psychotic
disorders, particularly bipolar disorder and depression. His greatest
contribution to the field is in the discovery and implementation of
novel therapies. He has published over 20 self-initiated, non-industry
randomised controlled trials, predominantly in bipolar disorder. He is a
past committee member of both the Collegium Internationale
Psychopharmacologicum and World Federation of Societies of Biological
Psychiatry is a member of a number of international advisory boards. He
was the founding editor of The Journal of Depression and Anxiety, is
associate editor of both the Australian and New Zealand Journal of
Psychiatry and Early Intervention in Psychiatry, has served as guest
editor or is on the editorial board of 12 other journals as well as
being a reviewer of 30 journals.
He is the recipient of a number of
grants, including a NHMRC CCRE and 3 NHMRC project grants, two
beyondblue grants and two Stanley Medical Research Institute awards and
is a lead investigator on the CRE for Mental Health. He is regularly
invited as a speaker at international meetings. In 2008, he was awarded
the Australasian Society of Psychiatric Research Eli Lilly Oration, the
Pathcare Smart Geelong Research and Learning Expo Health and Lifestyle
award and the G Force Recruitment Researcher Of The Year award for this
work, and in 2009 received a commendation in the Ministers Award for
Mental Health. Since relocating to Australia in 2001, he has established
a new research unit at Barwon Health, which now has 15 researchers and 6
students engaged in 33 projects, multiple, local national and
international collaborations, as well as heading a clinical Professorial
Unit at the Geelong Clinic.
Boris Birmaher,
MD
Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry
University of Pittsburgh School of Medicine, Western Psychiatric
Institute and Clinic, Pittsburgh, PA
Boris Birmaher, MD, is the Endowed Chair
in Early Onset Bipolar Disease and Professor of Psychiatry at the
University of Pittsburgh, School of Medicine. He has board
certifications in both general psychiatry and child psychiatry. He
received his medical degree from Valle University in Cali, Colombia and
completed; training in general psychiatry at the Hebrew University,
Hadassah Medical Center in Jerusalem, Israel; training in biological
psychiatry at the Albert Einstein College of Medicine in New York; and
training in child psychiatry at Columbia University, New York
Psychiatric Institute in New York.
Dr. Birmaher has been involved in
clinical work and research in pediatric mood and anxiety disorders for
over 25 years. His research interests include areas of phenomenology,
course and outcome, etiology, and pharmacology and psychosocial
treatments. He is currently involved in several NIMH studies including:
1) “Course and Outcome for Adolescents with Bipolar Illness,” aimed at
describing the phenomenology, course, and associated factors in children
and adolescents with bipolar spectrum disorder; 2) “Children of Bipolar
Parents: A High Risk Follow-up Study,” aimed at studying the
longitudinal psychopathology of children of parents with bipolar
disorder compared with children of community controls; and 3)
“Longitudinal Assessment of Manic Symptoms,” aimed at evaluating the
predictive value of early-onset manic symptoms in a large sample of
children ages 6-12 years old. Together with Dr. David Axelson, Dr.
Birmaher is the Co-Director of the Child and Adolescent Bipolar Services
(CABS) program, a program for the service, teaching and research of
bipolar disorder in youth.
Corin Bourne,
DPhil
Post-Doctoral Researcher, Department of Psychiatry, University of Oxford
Warneford Hospital, Oxford, United Kingdom
Corin Bourne holds bachelor degrees in Engineering (Loughborough
University of Science and Technology) and Psychology (University College
London, UCL) as well as a DPhil from the University of Oxford. Supported
by a Medical Research Council (MRC) scholarship, Corin’s DPhil research
used fMRI and other techniques to investigate the peri-traumatic
cognitive mechanisms involved in the formation of intrusive memories of
traumatic events. Corin is currently employed on a project funded by the
7th Framework of the European Commission: the European Network of
Bipolar Research Centres (ENBREC). ENBREC has been established to
develop and implement common tools and practices in the diagnosis,
assessment, care, and treatment of bipolar disorder across Europe.
Within ENBREC, the Oxford team has specific responsibility for
neuropsychological assessment of cognitive deficits associated with
bipolar disorder. Corin’s research interests are broad but are centred
on the interface between cognitive and clinical psychology; in
understanding how specific cognitions and cognitive processes contribute
to the development and maintenance of clinical disorders.
Charles L. Bowden,
MD
Nancy U. Karren Professor, Department of Psychiatry
University of Texas Health Science Center, San Antonio, Texas
Charles L. Bowden, MD is Nancy U. Karren
Clinical Professor in the Department of Psychiatry and Professor in the
Department of Pharmacology at The University of Texas Health Science
Center at San Antonio. He completed his training in psychiatry at the
New York State Psychiatric Institute and Columbia-Presbyterian Hospital
in New York, New York.
Dr. Bowden was awarded the 2001 Gerald L.
Klerman Senior Investigator Award by the Depression and Bipolar Support
Alliance, received the 2006 Mind of America Scientific Research Award
from the National Alliance for the Mentally Ill and the 2008 NARSAD
Falcone prize for outstanding achievement in affective disorders
research. Dr. Bowden is a Fellow of the American College of
Neuropsychopharmacology, the Collegium Internationale
Neuro-Psychopharmacologicum and a Corresponding Member of the European
College of Neuropsychopharmacology and a member of the Executive
Committee of the International Society for CNS Clinical Trials and
Methodology. He is Associate Editor for Acta Psychiatrica Scandinavica.
He has authored more than 400 publications. His research is principally
on the symptomatic and biological characterization of bipolar disorders
and the effectiveness and pharmacodynamics of mood stabilizing drugs. He
has been principal investigator for 90 studies funded by pharmaceutical
companies, NIMH, and various foundations. Dr. Bowden frequently serves
as consultant to pharmaceutical companies and governmental agencies and
is named in Best Doctors in the US in the area of mood disorders.
Joseph Calabrese,
MD
Bipolar Disorders Research Chair and Professor of Psychiatry, Case
Western Reserve University
Director, Mood Disorders Program at the University Hospitals Case
Medical Center, Cleveland, Ohio
Joseph Calabrese holds the Bipolar Disorders Research Chair and is
Professor of Psychiatry at Case Western Reserve University. He is the
Director of the Mood Disorders Program at the University Hospitals Case
Medical Center in Cleveland, Ohio. Dr. Calabrese also co-directs an NIMH-funded
‘Bipolar Disorders Research Centre, whose projects include research
conducted by Bob Findling (Director of Child and Adolescent Psychiatry)
on the phenomenology and treatment of juvenile bipolar, and research
conducted by Martha Sajatovic (Director of Geriatric Psychiatry), whose
projects include late life bipolar disorder, health services research,
and qualitative methodology.
The research center is dedicated to the improvement of clinical outcomes
in under-served populations of bipolar disorder, including those with
bipolar depression, rapid cycling, children and adolescents, adults
currently abusing alcohol and/or drugs, forensic complications of
bipolar disorder, those receiving care within community mental health
centres, older adults, and members of the Ohio National Guard.
Dr Calabrese has received numerous research grants from the NIMH and
Federal agencies and published over 300 peer-reviewed papers. His
primary scientific focus is the short- and long-term treatment of
bipolar disorder, with special emphasis on bipolar depression and the
rapid cycling pattern of presentation. Dr. Calabrese was chosen by
psychiatry residents to receive the ‘Best Teacher of the Year Award’ in
three different years, received the NARSAD Lifetime Achievement Award
for his research in bipolar disorder in 2005, Ellis Island Medal of
Honor in 2006, and the Gerald L. Klerman Lifetime Achievement Award in
2008.
Gabrielle A. Carlson,
MD
Professor of Psychiatry and Pediatrics and Director of the Division of
Child and Adolescent Psychiatry
State University of New York at Stony Brook
Gabrielle A. Carlson, M.D., has been
professor of Psychiatry and Pediatrics and Director of the Division of
Child and Adolescent Psychiatry at State University of New York at Stony
Brook since 1985. She did her undergraduate training at Wellesley and
subsequently obtained her MD degree from Cornell University Medical
College. She did her adult psychiatry training at Washington University
in St. Louis and at the National Institutes of Mental Health. She
completed a fellowship in Child and Adolescent Psychiatry at UCLA where
she subsequently taught on the faculty.
Dr. Carlson specializes in childhood
psychopathology and psychopharmacology in general, and the subjects of
childhood and adolescent depression and bipolar disorder, specifically.
She has written over 200 papers and chapters on those subjects and has
co-authored two books, Affective Disorders in Childhood Adolescence
(Spectrum Publications) and Psychiatric Disorders in Children and
Adolescents (W.B. Saunders). Her research interests include the
phenomenology and long term follow up of young people with bipolar
disorder, and the relationship of behavior disorders, developmental
disorders and mood disorders. Her most recent grants have focused on
those questions.
Dr. Carlson is active in the psychiatry community. She has served on
many national committees, editorial boards and various review committees
for the National Institute of Mental Health. She has been named in Best
Doctors in America, New York City and Long Island and Good
Housekeeping’s Best Mental Health Experts. She was recently awarded the
APA’s Blanche F. Ittleson Award for research in child and adolescent
psychiatry and the New York Academy of Child and Adolescent Psychiatry’s
Hulse Award. She is past president of the International Society for
Research in Child and Adolescent Psychopathology and is currently
Program Chair for the American Academy of Child and Adolescent
Psychiatry.
Francesc Colom,
PsyD, MSc, PhD
Head of the Psychoeducation and Psychological Treatments Area
Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University
of Barcelona), Spain
Francesc Colom, PsyD, MSc, PhD is the head of the Psychoeducation and
Psychological Treatments Area of the Barcelona Bipolar Disorders Program
(IDIBAPS- Hospital Clinic University of Barcelona). The Barcelona
Psychoeducation Program, designed by Dr. Colom and his colleagues, is
now the strongest evidence-based psychoeducational program for bipolar
patients. His book “Psychoeducation Manual for Bipolar Disorder” has
been published in several languages including, English, Spanish,
Italian, French, and Polish. He has lectured all over the world and
published over one hundred scientific articles with an H index of 32.
Dr. Colom has also written twelve books and a number of book chapters.
His current research focuses on psychological treatment and its
biomarkers of response, treatment adherence, pharmacological issues,
cognitive impairment and its remediation and on clinical issues such as
predominant polarity, mixed states, and temperament.
He has been a member of the Board of Councilors of the International
Society for Bipolar Disorders and a member of the Nomenclature Committee
and Chair of the Website Education Committee for the same society. He is
also is a member of the Scientific Advisory Panel of the ECNP. In
addition, he sits on the editorial board of five international
scientific journals and enjoys reviewing articles for more than thirty
others. In June, 2007, Francesc Colom was awarded the prestigious
“Mogens Schou Award” for the quality of his research.
Nancy
DiazGranados, MD, MS
Assistant Professor of Psychiatry, University of Texas Health Science
Center at San Antonio, San Antonio, TX
Nancy DiazGranados, MD, MS, joined the
faculty of the University of Texas Health Science Center at San Antonio
in September, 2010 as Assistant Professor of Psychiatry. She has a
master’s degree in pharmacology from Thomas Jefferson University and a
postdoctoral fellowship in experimental therapeutics from the National
Institute of Mental Health in Bethesa, MD. Dr. DiazGranados is a 2001
graduate from the Pontifica Universidad Javeriana School of Medicine in
Bogota, Colombia; and has developed a career in mood disorders research.
Her research focuses on experimental therapeutics with rapid acting
antidepressants for treatment resistant depression, bipolar depression,
and suicide ideation.
Faith B. Dickerson,
PhD, MPH
Director of Psychology, Sheppard Pratt, Baltimore, MD
Faith Dickerson, Ph.D., M.P.H. is the
director of psychology and the head of the Stanley Research Program at
Sheppard Pratt in Baltimore, Maryland. She is also a Clinical Associate
Professor of Psychiatry at the University of Maryland School of
Medicine. She received her Ph.D. from Columbia University. Her research
interests focus on bipolar disorder and schizophrenia. She has carried
out studies about infectious and inflammatory factors, cognitive
functioning, and social outcomes of these disorders. She has also
directed clinical trials of novel adjunctive medications and has been an
investigator on studies to improve the physical health of persons with
serious mental illness and to reduce disability in first episode
psychosis. Dr. Dickerson has authored or co-authored one
textbook and more than 100 scientific articles and book chapters.
Brent Forester,
MD
Director, Mood Disorders Division of the Geriatric Psychiatry Research
Program &
Site Director of the Harvard Medical School Psychiatry Clerkship at
McLean Hospital, Belmont, MA
Assistant Professor of Psychiatry, Harvard Medical School, Cambridge, MA
Dr. Forester is currently the Director of
the Mood Disorders Division of the Geriatric Psychiatry Research Program
and the Site Director of the Harvard Medical School Psychiatry Clerkship
at McLean Hospital in Belmont, MA and an Assistant Professor of
Psychiatry at Harvard Medical School. He completed a Masters of Science
Degree in June, 2009 through the joint Harvard - MIT Clinician
Investigator Training Program. From September 2002 through June, 2007
Brent served as the Medical Director of the Geriatric Neuropsychiatry
Unit at McLean Hospital. Before coming to McLean, he served as the
Clinical Director of Geriatric Psychiatry at the Mental Health Center of
Greater Manchester (in New Hampshire) and an Assistant Professor of
Psychiatry at Dartmouth Medical School focusing on geriatric mental
health services research.
Dr. Forester has been a principal
investigator in a number of research projects including clinical
psychopharmacology trials in bipolar disorder, geriatric depression and
the management of agitation in patients with dementia. Upon returning to
McLean Hospital in 2002, he began collaborating with the McLean Brain
Imaging Center and is now conducting studies utilizing magnetic
resonance spectroscopy to study markers of energy metabolism in late
life depression and bipolar disorder. In 2009, he received a K23 career
development award from the NIMH for a project studying lamotrigine in
geriatric bipolar depression which focuses on markers of brain energy
metabolism (glutamate, glutamine, lactate, NAA) as predictors of
clinical status and treatment response.
Dr. Forester is currently the Vice Chair
of the Teaching and Training Committee and member of the Board of
Directors of the American Association for Geriatric Psychiatry. He also
began a three year term as a Member of the Board of Directors of the
Alzheimer’s Association for MA and NH in July, 2009.
Dr. Forester has published a number of
articles and book chapters on topics including Geriatric Bipolar
Disorder, Brain lithium levels and effects on cognition and mood in
Geriatric Bipolar Disorder, the Behavioral and Psychological Symptoms of
Dementia and Late Life Psychosis. He is actively involved in teaching
Harvard Medical Students and McLean Hospital - Mass General Hospital
psychiatry residents.
Sophia Frangou,
MD, PhD
Reader in Psychiatry
Institute of Psychiatry, King’s College London, London, UK
Dr. Sophia Frangou is Reader in Psychiatry at the Institute of
Psychiatry, Kings College London where she heads the Section of
Neurobiology of Psychosis since 1997. Dr. Frangou graduated from the
Medical School of the University of Athens, Greece. She then moved to
the UK where she trained at the Maudsley Hospital, London. In parallel
with her psychiatric training she obtained a Masters Degree in
Neuroscience and a doctoral degree from the University of London. Dr.
Frangou’s research work focuses on the investigation of the
pathophysiological processes underlying psychosis using clinical,
cognitive and neuroimaging techniques. Research into the aetiology and
pathophysiology of psychosis is vital for providing a theoretical
framework for developing long-term treatment strategies. She has
received numerous awards including the Psychopharmacology Prize from the
Royal College of Psychiatrists. Dr. Frangou is the Editor of “European
Psychiatry”, the official Journal of the European Psychiatric
Association. She is a Fellow of the Royal College of Psychiatrists and
of the European Psychiatric Association. She has served on the Council
of the British Association for Psychopharmacology (BAP) and co-authored
the BAP guidelines for the treatment of Bipolar Disorder. She is
Secretary and founding member of the EPA Section of NeuroImaging and
heads the Brain Imaging Network of the European College of
Neuropsychopharmacology.
Debra Frankel,
LCSW
Depression and Manic Depression Prevention Program
University of Pittsburgh School of Medicine and Western Psychiatric
Institute and Clinic, Pittsburgh, PA
Debra Frankel is a trainer, supervisor and clinician at the University
of Pittsburgh School of Medicine in the Depression and Manic Depression
Prevention Program at Western Psychiatric Institute and Clinic. She was
originally trained in Interpersonal Psychotherapy in 1985 and has
treated numerous mood disorder patients using this modality. Ms. Frankel
helped to modify interpersonal psychotherapy for bipolar disorder
patients and has been training and supervising clinicians in IPSRT since
1995. She has participated in clinical trials involving both
Interpersonal Therapy and Interpersonal Therapy and Social Rhythms
Therapy. She serves as a training supervisor for research clinicians.
She is a clinical supervisor at the University of Pittsburgh Graduate
School in Psychology. She has a private practice specializing in mood
and anxiety disorders. She received her undergraduate degree from Kenyon
College in 1978 and her master’s degree from Columbia University School
of Social Work in 1980.
Mark A. Frye, MD
Chair and Professor of Psychiatry, Department of Psychiatry & Psychology
Director, Integrated Mood Group, Mayo Clinic, Rochester, MN
Dr. Frye is Chair of the Department of
Psychiatry & Psychology, Mayo Clinic. He received his medical degree
from the University of Minnesota and completed his psychiatric training
at the UCLA Neuropsychiatric Institute. He completed a subsequent
research fellowship in the Biological Psychiatry Branch at the National
Institute of Mental Health (NIMH) in Bethesda, Maryland. While at NIMH,
his area of research was focusing on the neurobiology of depression and
bipolar disorder.
Formerly the Director of the UCLA Bipolar
Disorder Research Program (1998-2006), he is now Director of the
Integrated Mood Group at Mayo Clinic. His clinical interests are in mood
disorders (bipolar disorder, treatment resistant depression) with a
research focus in clinical trials, pharmacogenomics, and brain imaging.
He has received numerous honors and
awards both as an educator and researcher, including three UCLA
departmental medical student and resident teaching awards and the Gerald
Klerman Young Investigator Award from the Depression and Bipolar Support
Alliance.
His research funding has been from the
National Institute of Mental Health (NIMH), National Institute of
Alcohol Abuse and Alcoholism (NIAAA), The Stanley Medical Research
Institute, The American Foundation for Suicide Prevention, and industry.
He is an active author, publishing more than 150 papers in peer-reviewed
publications. Dr. Frye is on the Scientific Advisory Committee to the
Depression and Bipolar Support Alliance and is the Vice President of
Global Outreach for the International Society for Bipolar Disorders.
John R. Geddes,
MD, FRCPsych
Professor of Epidemiological Psychiatry, Department of Psychiatry,
University of Oxford, Oxford, UK
John R. Geddes is Professor of
Epidemiological Psychiatry at University of Oxford, UK. His current
research focuses on conducting large scale randomized clinical trials
and using research synthesis methods including systematic overviews and
meta-analysis to inform clinical practice. Professor Geddes is Director
of the Oxford Clinical Trials Unit for Mental Illness. Professor Geddes
is Honorary Consultant Psychiatrist at the Oxfordshire and
Buckinghamshire Mental Health NHS Foundation Trust where he provides
clinical care for patients with mood disorders, specialising in bipolar
disorder. Professor Geddes is a Fellow of the Royal College of
Psychiatrists and, in 2010 was named Academic Psychiatrist of the Year
by the Royal College of Psychiatrists. In 2008, he was awarded an
Honorary Fellowship of the American College of Psychiatrists. Professor
Geddes has authored or co-authored, more than 150 scientific articles
and book chapters and 4 books.
Elizabeth L. George,
PhD
Licensed Clinical Psychologist, Research Associate, University of
Colorado, Boulder, CO
Dr. George received her bachelor’s degree in English and Psychology at
the University of North Carolina in Chapel Hill. She received her Ph.D.
in Clinical Psychology from the University of Colorado in Boulder. She
completed her residency at the Denver Veterans Administration Medical
Center. Dr. George is a research associate at the University of
Colorado-Boulder where she provides treatment, supervises, and continues
to develop treatment outcome programs.
Dr. George has done extensive research in treatment development for
bipolar disorder. She has spent 20 years involved in treatment outcome
research for adult and adolescent bipolar disorder. She helped to
develop Integrated Family and Individual Treatment (IFIT) for bipolar
disorder. She co-wrote the manual for Family Focused Treatment (FFT) for
adolescent bipolar disorder. Currently she is involved in an ongoing
three site FFT treatment outcome study involving 150 families with an
adolescent who has bipolar disorder. Dr. George has co-written a manual
on a prevention treatment for youth (9-17) at risk for developing
bipolar disorder and is involved in a two site outcome study for the at
risk population. Dr. George and Dr. David Miklowitz have written a book
for parents entitled The Bipolar Teen: What you can do to help your
child and your family (2008) describing identification and treatment of
adolescent bipolar disorder. Dr. George also provides trainings and
lectures on many aspects of the bipolar condition and its treatment
including comorbidity and managing bipolar in the academic environment.
In addition, Dr. George has an active private practice that primarily
focuses on prevention and treatment of bipolar II and the bipolar
spectrum disorders. She is also the community advisor for the Boulder
chapter of the Depression and Bipolar Support Alliance (DBSA). She
continues to be interested in finding new ways to understand and treat
this medically complicated illness.
S. Nassir Ghaemi,
MD, MPH
Director, Mood Disorders and Psychopharmacology Programs, Tufts Medical
Center, Boston, MA
S. Nassir Ghaemi MD, MPH is a psychiatric researcher with expertise in
bipolar disorder, and training in philosophy and public health. He is
the author of A Clinician's Guide to Statistics and Epidemiology in
Mental Health: Measuring Truth and Uncertainty, published in 2009 by
Cambridge University Press. Previous books he has authored include The
Concepts of Psychiatry: A Pluralistic Approach to the Mind and Mental
Illness (Baltimore, Maryland: Johns Hopkins University Press, 2003,
2007), as well as the 2nd edition of Mood Disorders: A Practical Guide
(Baltimore, Maryland: Lippincott, Williams, and Wilkins; 2003, 2007). He
has also published over 100 scientific articles or book chapters, and
serves on the editorial board of numerous journals. He also serves on
the executive committee of the Association for the Advancement of
Philosophy and Psychiatry; is a Distinguished Fellow of the American
Psychiatric Association; and has served as chairman of the Diagnostic
Guidelines Task Force of the International Society for Bipolar Disorders
(2005-2008). Dr. Ghaemi obtained his medical degree at the Medical
College of Virginia (MCV) in Richmond, completed a medical internship at
Massachusetts General Hospital (MGH) in Boston, psychiatry residency at
McLean Hospital in Belmont, Massachusetts, and a research
psychopharmacology fellowship in mood disorders at MGH, followed by
faculty positions at George Washington University, Harvard Medical
School, and Emory University. He also received a Master of Arts degree
in philosophy from Tufts University in 2001 and a Master of Public
Health degree in the Clinical Effectiveness Program from the Harvard
School of Public Health in 2004.
Ariel G.
Gildengers, MD
Assistant Professor of Psychiatry, Department of Psychiatry, University
of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA
Dr. Gildengers is Assistant Professor of
Psychiatry at the University of Pittsburgh School of Medicine and the
Western Psychiatric Institute and Clinic. He is an active clinical
investigator, whose research focuses on the assessment and treatment of
bipolar disorder in older adults. He graduated from the Massachusetts
Institute of Technology and the New Jersey Medical School, and completed
his post-graduate medical training at the University of Pittsburgh
Medical Center and Western Psychiatric Institute and Clinic. Dr.
Gildengers received an NIMH K23 Research Career Award to investigate the
relationship between bipolar disorder and cognitive function and is
currently the Principal Investigator of a five-year longitudinal study
examining cognitive function in older adults with bipolar disorder.
Benjamin I.
Goldstein, MD, PhD
Assistant Professor of Psychiatry
University of Toronto Faculty of Medicine and Sunnybrook Health Sciences
Centre
Toronto, Ontario, Canada
Dr. Goldstein was previously at the University of Pittsburgh and the
Western Psychiatric Institute and Clinic from 2006-2009 where he retains
an adjunct faculty appointment. He completed his medical degree at the
University of Calgary in 2001 and psychiatric residency at the
University of Toronto in 2006. Dr. Goldstein’s clinical and research
efforts focus on children and adolescents with bipolar disorder and
offspring of parents with bipolar disorder. His specific interests
within this population include substance abuse and medical comorbidity
as well as peripheral biomarkers. He has authored more than 40
scientific articles. He is the recipient of several national and
international awards including the APA/AstraZeneca Young Minds in
Psychiatry Award, the Robinson-Cunningham Award from the American
Academy of Child and Adolescent Psychiatry, and the Samuel Gershon Award
from the International Society for Bipolar Disorders.
Jodi M. Gonzalez,
PhD
Associate Professor, University of Texas Health Science Center in San
Antonio, TX
Jodi M. Gonzalez obtained her PhD in Counseling Psychology from the
University of North Texas in 1999. Her internship and postdoctoral
fellowship were completed at the University of Texas Health Science
Center at San Antonio, with an emphasis on clinical research. Dr.
Gonzalez joined the faculty as an assistant professor at the University
of Texas Health Science Center in San Antonio in the Mood and Anxiety
Disorders Division in 2000. She is a recipient of a 2007 NARSAD Young
Investigator Award to develop and manualize psychodynamic psychotherapy
techniques in complicated bipolar disorder. She is currently involved in
several community-based research projects and serves as the chair of the
Diversity Committee of the multi-site Bipolar Trials Network. Additional
areas of research interest and publications are: psychosocial treatment
in bipolar disorder, attitudes toward mental health treatment, adherence
to treatments, and the impact of ethnicity/race in each of these areas.
She lectures and supervises medical students, psychiatry and psychology
residents. In particular, she supervises and teaches in psychotherapy
models and treatments. Dr. Gonzalez is a licensed psychologist and
provides individual and family psychotherapy for adolescents and adults.
Guy Goodwin,
DPhil, FMedSci
W A Handley Professor of Psychiatry, University of Oxford, Oxford,
England
Guy Goodwin trained in medicine and completed a DPhil in physiology at
Oxford. After training in psychiatry he was for 10 years Clinical
Scientist and Consultant Psychiatrist in the MRC Brain Metabolism Unit
in Edinburgh. Since 1996 he has been Professor of Psychiatry and head of
the University department in Oxford. Dr. Goodwin’s research interests
are in the treatment of severe psychiatric illness and the application
of neuroscience in understanding the neurobiology of mood disorder.
Currently, he is involved in projects on the neurobiology of
vulnerability to mood disorder, the psychopharmacology of emotional
processing. He has also helped develop the basis for larger scale
pragmatic clinical trials in bipolar affective disorder (BALANCE and
CEQUEL). Dr. Goodwin has served as a member of the Wellcome Trust
Neurosciences Panel, the Council of the British Association for
Psychopharmacology, the Clinical fellowships panel and Advisory Board of
the MRC and the French ANR. He was president of the British Association
for Psychopharmacology 2002-2004, is a Fellow of ACNP and President
elect of ECNP. He has published over 300 refereed papers and book
chapters. He has acted as a reviewer for numerous journals including the
American Journal of Psychiatry, The Archives of General Psychiatry, and
Biological Psychiatry. Dr. Goodwin remains directly involved in patient
care, almost exclusively focused on bipolar disorders.
Paul Grof, MD, PhD,
FRCPC(C)
Director of Mood Disorders Center of Ottawa and Professor of Psychiatry
at the University of Toronto, Canada
Paul Grof initially worked as a research
psychiatrist in the Psychiatric Research Institute in Prague, and as a
fellow in psychoendocrinology of affective disorders in West Germany.
Since the fall of l968 Dr. Grof was a research psychiatrist and faculty
member at McMaster University, Canada, and spent l977 - l978 as a
Visiting Scientist at the National Institute of Mental Health in
Bethesda, Maryland. Dr. Grof became Director of Research and Education
at a teaching hospital of McMaster University, and l985 -2000 was active
as Expert of the World Health Organization and as Visiting Professor at
several European Universities. From l988 to 1993 Dr. Grof was Clinical
Director of the Royal Ottawa Hospital and subsequently directed there
clinical and research activities in mood disorders. Currently he is
Director of Mood Disorders Center of Ottawa and Professor of Psychiatry
at the University of Toronto. He authored and co-authored over 450
papers and book chapters and 3 books.
Allison G. Harvey,
PhD
Professor of Psychology, Department of Psychology, University of
California, Berkeley, CA
Allison G. Harvey, PhD., completed her
clinical and research training in Sydney, Australia, a post doctoral
fellowship and her first faculty position at the University of Oxford
before moving to the Psychology Department at UC Berkeley in 2004. Dr.
Harvey is a licensed clinical psychologist and she is certified in
Behavioral Sleep Medicine. She is also an adjunct professor at the
University of Bergen, Norway. Dr. Harvey’s research focuses on
understanding the role of sleep disturbance across psychiatric
disorders, particularly bipolar disorder. Dr. Harvey has authored over
150 scientific articles and book chapters and authored two books. She
has been the recipient of numerous awards, including The Queen’s Trust
Award, the Chaim Danielle Award for Traumatic Stress Studies and an
Honorary Doctorate from the University of Örebro, Sweden. Dr. Harvey has
received research funding from the Royal Society, Wellcome Trust, NARSAD
and the National Institutes of Mental Health.
Roger F. Haskett,
MD
Professor of Psychiatry
University of Pittsburgh School of Medicine and Western Psychiatric
Institute and Clinic, Pittsburgh, PA
Dr. Haskett joined the faculty at the
University of Pittsburgh School of Medicine and Western Psychiatric
Institute and Clinic in 1992 as Professor of Psychiatry. He received his
medical and psychiatric training at the University of Melbourne in
Australia, followed by a clinical research fellowship and 11 years on
the faculty at the University of Michigan Medical School. Dr. Haskett’s
research has addressed the neurobiology and treatment of depression and
bipolar disorder, including factors that will improve outcomes after
electroconvulsive therapy (ECT). His clinical practice emphasizes the
diagnostic evaluation and pharmacologic treatment of patients with
severe mood disorders and their frequent need for long-term medical
management. Dr. Haskett is a Distinguished Life Fellow of the American
Psychiatric Association and a past President of the Pennsylvania
Psychiatric Society. Dr. Haskett is a member of the editorial board of
the Journal of ECT and has been elected to the membership of the
American College of Psychiatrists.
Chantal Henry, MD,
PhD
Professor of Psychiatry, University of Paris-EST and Chenevier Hospital,
Créteil, France
Chantal Henry, MD, PhD, joined the faculty of the University of Paris-Est
in September, 2008 as Professor of Psychiatry after 14 years at the
Bordeaux hospital. Dr. Henry’s research focuses on the characterization
and treatment of bipolar disorders. She works also on the identification
of relevant phenotypes for genetic studies on bipolar disorders. Since
2008, Dr. Henry has been in charge of the organization of French
networks of expert centres on bipolar disorders, schizophrenia and
Asperger. She coordinates also a European project: ENBREC (European
Network of Bipolar Research Expert Centres). Dr. Henry has authored or
co-authored more than 100 scientific articles, book chapters and books.
Amir Kalali MD
Professor of Psychiatry, University of California San Diego
Vice President, Medical and Scientific Services, and Global Therapeutic
Team Leader CNS
Quintiles Inc., San Diego, CA
Dr. Kalali is currently Vice President,
Medical and Scientific Services, and Global Therapeutic Team Leader CNS,
at Quintiles Inc., focusing on developing novel compounds for the
treatment of disorders of the central nervous system. He is globally
responsible for the medical and scientific aspects of development
programs in psychiatry and neurology. He is also Professor of Psychiatry
at University of California San Diego.
Dr. Kalali is active in facilitating
scientific collaboration between academia, government, and
pharmaceutical industry scientists. He was the Founding Chairman of the
Executive Committee of the International Society for CNS Drug
Development (ISCDD), and currently the Executive Secretary. He is also
active in the International Society for CNS Clinical Trials and
Methodology (ISCTM), where he is a member of the Executive Committee and
the Scientific Committee, and chairs the Publication Committee. He has
also been involved in the effort which resulted in the launch of the CNS
Summit in 2010.
Dr. Kalali has been an academic
investigator in over 70 psychopharmacological clinical trials and at
Quintiles has had medical and scientific responsibility for over 300
clinical trials. He is an expert in CNS clinical trial methodology,
including clinical rating scales, and has trained investigators from
over forty countries. Dr. Kalali is the Editor of the
journal Innovations in Clinical Neuroscience, and is on the editorial
board of several other journals. He has published widely in journals
such as the Archives of General Psychiatry, The American Journal of
Psychiatry, and the British Journal of Psychiatry.
Dr. Kalali is an active member of many
professional societies including the American College of
Neuropsychopharmacology, the American Society for Clinical
Psychopharmacology, the American Psychiatric Association, the Canadian
College of NeuroPsychopharmacology, the Collegium Internationale Neuro
Psychopharmacologicum, the Drug Information Association, the
International Society for CNS Drug Development, the International
Society for CNS Clinical Trials and Methodology, the Royal College of
Psychiatrists, United Kingdom, and the Society for Neuroscience.
Terence Ketter,
MD
Chief, Stanford University Bipolar Disorders Clinic and Professor of
Psychiatry and Behavioral Sciences
Stanford University, Palo Alto, CA
Terence Ketter received his medical
degree from the University of Toronto, completed internship and
residency training at the University of California San Francisco, and
fellowship training in psychopharmacology and brain imaging and at the
National Institute of Mental Health in Bethesda. He is Chief of the
Stanford University Bipolar Disorders Clinic and Professor of Psychiatry
and Behavioral Sciences. Dr. Ketter’s research interests include the use
of brain imaging methods such as magnetic resonance imaging (MRI),
magnetic resonance spectroscopy (MRS), and positron emission tomography
(PET) to better understand the neurobiology of mood disorders and to
explore the possibility of using these techniques to more effectively
target treatments for patients with bipolar disorders. Dr. Ketter has
also done research in the use of novel medications and combinations of
medications in the treatment of bipolar disorders, with an emphasis on
the use of anticonvulsants and second generation antipsychotics and the
comparative effectiveness of different pharmacotherapies. Recently his
research group's work has revealed new insights into the links between
creativity, temperament, and mood disorders. His research in these areas
has been published extensively. He has published over 300 scientific
articles and book chapters and is the editor of the books “Advances in
the Treatment of Bipolar Disorder” and “Handbook of Diagnosis and
Treatment of Bipolar Disorder”.
Amy M. Kilbourne,
PhD, MPH
Associate Professor of Psychiatry, University of Michigan
Associate Director, VA National Serious Mental Illness Treatment
Resource and Evaluation Center, Ann Arbor, MI
Dr. Kilbourne’s research is focused in three primary areas: 1)
implementation of behavioral interventions for bipolar and other mental
disorders, 2) integrated mental health and medical care models; and 3)
application of large outcomes databases to inform mental health policy
and practice. Her goal is to improve quality and outcomes of care for
persons with mental disorders, and she has been widely recognized for
her work in implementation science, integrated mental health and primary
care, and preventable mortality in mental health. Notably, Dr. Kilbourne
has implemented Life Goals Collaborative Care, a program combining best
practices in chronic care management and behavioral change for persons
with bipolar and other mental disorders. She has also adapted a
groundbreaking implementation model (Replicating Effective Programs) to
facilitate the uptake of evidence-based programs in community-based
settings. She has several national grants and over 100 peer-reviewed
scientific articles, and serves on several national committees including
the National Network of Depression Centers Interventions Dissemination
Workgroup and the VA Mental Health Quality Enhancement Research
Initiative. She is sought out for her expertise in implementation
methods, evidence-based psychosocial and behavioral interventions, and
application of large outcomes databases to understand and reduce
preventable mortality in mental disorders throughout the United States
and internationally. She also regularly consults with decision makers at
community-based practices on implementing interventions to integrate
care and improve quality for persons with mental disorders. After
receiving her MPH in epidemiology and PhD health services from the
University of California, Los Angeles, Dr. Kilbourne joined RAND Health
(Santa Monica, CA), and was then appointed Assistant Professor of
Medicine and Psychiatry at the University of Pittsburgh in 1999.
Fouzia
Laghrissi-Thode, MD
Head of Global Product Strategy for Metabolism and Anaemia
F. Hoffmann-La Roche, Basel, Switzerland
Fouzia Laghrissi-Thode, M.D., is Head of
Global Product Strategy for Metabolism and Anaemia at F. Hoffmann-La
Roche., based in Basel, Switzerland. She joined Roche in 2000 as a CNS
Leader in the New Medicines Strategy Marketing Department and in 2001
was appointed CNS Business Development Director in Pharma Partnering. In
2003 her responsibilities were extended to leading the business
development Primary Care activities including CNS, Cardiovascular and
Genito-Urinary disease areas. She was appointed Lifecycle Leader for
dalcetrapib for cardiovascular diseases in 2006 and lead the dal-HEART
program with more than 15 000 patients.
Prior to joining Roche, Dr.
Laghrissi-Thode was a CNS Senior Clinical Research Physician at Novartis
Pharma in Basel. She holds an appointment as an Adjunct Professor of
Psychiatry at the University of Pittsburgh School of Medicine, USA. As a
Principal Investigator she conducted a number of studies in depressed
elderly and medically ill patients, and actively participated as
co-investigator in the research conducted by the NIMH CRC for the Study
of Affective Disorders and Late Life Mood Disorders. Her research was
recognized by the N.I.M.H. and the American Federation of Aging Research
Award (AFAR).
After graduating in Medicine at the
University of Tours, France, in 1987, she specialized in Psychiatry and
received her European board certification in 1992.
Marion Leboyer,
MD, PhD
Professor of Psychiatry, University of Paris
Department of Psychiatry and Psychiatry Genetic Lab, INSERM
Paris, FRANCE
Marion Leboyer, MD, PhD is Professor of
Psychiatry at the University of Paris and also serves as the head of the
university-affiliated Department of Psychiatry at the Hospital
Chenevier-Mondor in France. Dr. Leboyer is also the Director of the
Psychiatry Genetics Laboratory for the French National Institute of
Health and Medical Research (INSERM).
Dr. Leboyer also serves as the Director
of FondaMental, a foundation created by the French Ministry of Research
aiming at creating a network of expert centers and promoting research in
Psychiatry. FondaMental’s core objectives focus on better detection and
diagnosis of psychiatric disorders; improving the understanding of their
causes; training; and more effective communication strategies for
addressing the stigma of mental health disorders. The organization is
currently focusing on the most severe psychiatric disorders: bipolar
disorder; schizophrenia; autism (particularly high functioning autism);
suicide; and depression. Dr. Leboyer’s research efforts have contributed
to a better identification of relevant phenotypes for genetic studies,
particularly in the field of bipolar disorder, schizophrenia, suicide,
autism, OCD and pharmaco-genetic studies.
Dr. Leboyer is a dedicated translational
research scientist who has formed productive collaborative relationships
with colleagues around the world. As the Principal Investigator of
national and international studies, she has been able to produce
prominent findings such as the identification in autism of the first
mutations in neuroligins (NLGN-3 and NLGN-4). Dr. Leboyer has
disseminated her work through a publication portfolio of more than 200
scientific articles and book chapters, as well as 5 books, and is a
popular lecturer at conferences and professional meetings throughout the
world.
Andrew C. Leon, PhD
Professor of Biostatistics in Psychiatry, Professor of Public Health and
DeWitt Wallace Senior Scholar
Weill Cornell Medical College, White Plains, New York
Andrew C. Leon, Ph.D. is Professor of
Biostatistics in Psychiatry, Professor of Public Health and a DeWitt
Wallace Senior Scholar at Weill Cornell Medical College. His ongoing
NIMH-funded research has developed and evaluated statistical techniques
for treatment effectiveness analyses in longitudinal, observational
studies. He is also examining methods of accounting for the problem of
nonequivalent comparison groups in cluster randomized controlled
clinical trials. He served as a member of the Psychopharmacologic Drugs
Advisory Committee of the US Food and Drug Administration from 2002-2007
and testified before the US Congress, Committee on Veterans Affairs
hearing Exploring the Relationship between Medication and Veteran
Suicide in February, 2010. Dr. Leon is a member of the Executive
Committee of the International Society of CNS Clinical Trails and
Methodology (ISCTM) and served as Chair of the ISCTM Scientific Program
Committee from 2009-2011. He has published over 200 articles in the
fields of biostatistics, research methodology, and clinical psychiatry.
He is an Associate Editor of Statistics in Medicine and on the Editorial
Board of Journal of Clinical Psychiatry.
David A. Lewis, MD
Professor in Translational Neuroscience and Chairman
Department of Psychiatry, University of Pittsburgh
Director of the Translational Neuroscience Program
Medical Director and Director of Research, Western Psychiatric Institute
and Clinic, Pittsburgh, PA
Dr. Lewis is the UPMC Endowed Professor
in Translational Neuroscience and Chairman, Department of Psychiatry,
University of Pittsburgh; Director of the Translational Neuroscience
Program; and Medical Director and Director of Research, Western
Psychiatric Institute and Clinic. He also serves as Director of an NIMH
Conte Center for the Neuroscience of Mental Disorders, which is focused
on understanding the role of prefrontal cortical dysfunction in the
pathophysiology of schizophrenia. He received his medical degree from
the Ohio State University, completed residencies in internal medicine
and in psychiatry at the University of Iowa, and received his research
training at the Research Institute of the Scripps Clinic. Dr. Lewis has
published over 350 scientific articles. He has received NIMH Senior
Scientist and MERIT Awards, a Distinguished Investigator Award from
NARSAD and is a Fellow in the American College of
Neuropsychopharmacology and in the American College of Psychiatrists. He
is a member of the Institute of Medicine of the National Academy of
Sciences and serves on the National Advisory Mental Health Council. He
is also a Deputy Editor of The American Journal of Psychiatry and of
Neurobiology of Disease. Recognition of Dr. Lewis’ research
accomplishments has included the Lieber Prize for Schizophrenia Research
from NARSAD, the William K. Warren Award from the International Congress
of Schizophrenia Research, the Stanley Dean Research Award from the
American College of Psychiatrists, and the APIRE/Kempf award for
mentorship from the American Psychiatric Association.
Dr. Lewis’ research activities focus on the neural circuitry of the
prefrontal cortex and related brain regions, and the alterations of this
circuitry in schizophrenia. The research strategy underlying these
investigations involves several components. First, the normal functional
architecture of the prefrontal cortex, including its connections with
other cortical and subcortical regions, is examined using the macaque
monkey as a model system for the human brain. Within these circuits, the
expression and cellular localization of specific gene products, and how
these change in an activity-dependent fashion, are investigated. The
electrophysiological properties of intrinsic prefrontal cortical
circuits are studied using an in vitro slice preparation. Second, the
postnatal development of prefrontal cortical circuitry is characterized,
with special emphasis placed on maturational events, such as
synaptogenesis and synaptic pruning, which occur during early postnatal
life and adolescence. The timing and specificity of these processes are
examined for their possible contribution to the emergence and refinement
of the types of cognitive abilities that are disturbed in schizophrenia.
Third, based on the results of these lines of investigation, hypotheses
are generated regarding the elements of neural circuitry that may be
dysfunctional in schizophrenia. These hypotheses are then tested in
postmortem human brain specimens from subjects with schizophrenia.
Fourth, the primate model system is used to assess the influence of
psychotropic medications on the neural circuits of interest, and mouse
genetic models are used as “proof of concept” tests of the cause-effect
relationships between the alterations observed in the disease state. The
goal of these studies is to define the pathogenetic mechanisms and
pathophysiological processes that give rise to the cognitive deficits of
schizophrenia. Finally, these findings are used to identify potential
targets for novel therapeutic interventions that are examined in Phase
II clinical trials.
Gin S. Malhi, MD,
FRCPsych, FRANZCP
Chair, Discipline of Psychiatry, Sydney Medical School, University of
Sydney
Director, CADE Clinic, Royal North Shore Hospital, Sydney, Australia
Professor Gin Malhi is the Head of the
Discipline of Psychiatry at Sydney University. He is also the clinical
director of the CADE Clinic research unit (www.cadeclinic.com) and in
addition to conducting clinical research he teaches medical students at
Sydney Medical School and registrars at Royal North Shore Hospital. He
has a longstanding interest in mood disorders particularly bipolar
disorder and depression, and in recent years has increasingly used
clinical and neuropsychological assessments in conjunction with
neurobiological probes, to investigate the neural basis of affective
disorders. He has published more than 250 papers and is currently Editor
of The Australian and New Zealand Journal of Psychiatry.
Husseini K. Manji,
MD, FRCPC
Visiting Professor, Duke University, Durham, North Carolina
Global Therapeutic Head, Neuroscience
Johnson & Johnson Pharmaceutical Research and Development, Titusville,
NJ
Husseini K. Manji, MD is Global
Therapeutic Head, Neuroscience, Johnson and Johnson Pharmaceutical
Research and Development. He was previously Chief, Laboratory of
Molecular Pathophysiology & Experimental Therapeutics, NIH, and director
of the NIH Mood and Anxiety Disorders Program, the largest program of
its kind in the world. He is also a visiting professor at Duke
University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the
University of British Columbia. Following residency training, he
completed fellowship training at the NIMH and obtained extensive
additional training in cellular and molecular biology at the NIDDK. The
major focus of his research has been the investigation of disease- and
treatment-induced changes in gene and protein networks that regulate
synaptic and neural plasticity in neuropsychiatric disorders. His work
has helped to conceptualize these illnesses as genetically-influenced
disorders of synaptic and neural plasticity, and has led to the
investigation of novel therapeutics for refractory patients. He has also
been actively involved in the development of biomarkers to help refine
these multifactoral diseases into mechanism-based subcategories to
develop targeted therapeutics. Dr. Manji is a previous recipient of
numerous research awards, including the NIMH Director's Career Award for
Significant Scientific Achievement, the A. E. Bennett Award for
Neuropsychiatric Research, the Ziskind-Somerfeld Award for
Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens
Schou Distinguished Research Award, the American College of
Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished
research, the Canadian Association of Professors Award, the Brown
University School of Medicine Distinguished Researcher Award, the DBSA
Klerman Senior Distinguished Researcher Award, the American Federation
for Aging Research Award of Distinction, and the NIMH award for
excellence in clinical care and research.
In addition to his neuroscience research,
and biomarker and therapeutics development endeavors, Dr. Manji has also
been actively involved in medical and neuroscience education
undertakings, and has served as a member of the National Board of
Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard
Hughes Medical Institute Research Scholars Program Selection and
Advisory Committee, and numerous national curriculum committees. He has
developed and co-directed the NIH Foundation for the Advanced Education
in the Sciences Graduate Course in the Neurobiology of Neuropsychiatric
Illness, has received both the NIMH Mentor of the year and NIMH
Supervisor of the year awards, and the Henry and Page Laughlin
Distinguished Teacher Award. He has published extensively on the
molecular and cellular neurobiology of severe neuropsychiatric disorders
and the development of novel therapeutics. He has been editor of
Neuropsychopharmacology Reviews: the next generation of progress, deputy
editor of Biological Psychiatry, associate editor of the journal Bipolar
Disorders, and sits on the editorial board of numerous journals. Dr.
Manji has been inducted into the National Academy of Sciences’ Institute
of Medicine (IOM), is a Councilor of both the ACNP and Society of
Biological Psychiatry, co-chairs the NIH Biomarkers Neuroscience
Steering Committee, chaired the ACNP’s Task Force on New Medication
Development, and is immediate past president of the Society of
Biological Psychiatry.
David J. Miklowitz,
PhD
Professor Psychiatry, Director, UCLA Child and Adolescent Mood Disorders
Program
Director, Integrative Study Center in Mood Disorders
UCLA Semel Institute, David Geffen School of Medicine, UCLA, Los
Angeles, CA
Senior Clinical Researcher, Department of Psychiatry, Warneford
Hospital, Oxford University, Oxford, UK
Dr. Miklowitz is Professor of Psychiatry
in the Division of Child and Adolescent Psychiatry at the UCLA Semel
Institute, and a Senior Clinical Research Fellow in the Department of
Psychiatry at Oxford University. He completed his undergraduate work at
Brandeis University and his doctoral (1979-1985) and postdoctoral
(1985-1988) work at UCLA. His research focuses on family environmental
factors and family psychoeducational treatments for adult-onset and
childhood-onset bipolar disorder.
Dr. Miklowitz received the Joseph
Gengerelli Dissertation Award from UCLA (1986), Young Investigator
Awards from the International Congress on Schizophrenia Research (1987)
and the National Alliance for Research on Schizophrenia and Depression (NARSAD;
1987), a Faculty Research Award (1998) and a Faculty Teaching Award
(2008) from the University of Colorado, and a Distinguished Investigator
Award from NARSAD (2001). He won the 2005 Mogens Schou Award for
Research from the International Society for Bipolar Disorders and the
2008 Clinical Researcher of the Year award from Emory University. He
also won the 2009 Gerald L. Klerman Senior Research Investigator Award
from the Depressive and Bipolar Support Alliance. He has received
funding for his research from the National Institute of Mental Health,
the John D. and Catherine T. MacArthur Foundation, the Robert Sutherland
Foundation, and the Danny Alberts Foundation.
Dr. Miklowitz has published 225 research
articles and book chapters on bipolar disorder and schizophrenia, and
six books. His articles have appeared in the Archives of General
Psychiatry, the American Journal of Psychiatry, the British Journal of
Psychiatry, the Journal of Nervous and Mental Disease, Biological
Psychiatry, the Journal of Consulting and Clinical Psychology, and the
Journal of Abnormal Psychology. His book with Michael Goldstein, Bipolar
Disorder: A Family-Focused Treatment Approach (Guilford), won the 1998
Outstanding Research Publication Award from the American Association for
Marital and Family Therapy. His book “The Bipolar Disorder Survival
Guide” has sold over 200,000 copies, and is now out in a second edition.
His latest book, co-edited with Dante Cicchetti, is titled
"Understanding Bipolar Disorder: A Developmental Psychopathology
Perspective."
Andrew A.
Nierenberg, MD
Professor of Psychiatry, Harvard Medical School
Director of the Bipolar Research Program, Associate Director, Depression
Clinical and Research Program
Massachusetts General Hospital (MGH), Boston, MA
Dr. Nierenberg is Professor of
Psychiatry, Harvard Medical School, Director of the Bipolar Research
Program, and Associate Director of the Depression Clinical and Research
Program, Massachusetts General Hospital (MGH). He attended the Albert
Einstein College of Medicine of Yeshiva University followed by a
residency in psychiatry at New York University/Bellevue Hospital and
then became a Robert Wood Johnson Clinical Scholar at Yale University.
Dr. Nierenberg then ran one of the Affective Disorders Inpatient Units
and the Affective Disorders Outpatient Unit at McLean Hospital in
Belmont, MA. In 1992, he joined the Psychiatry Department at MGH.
He has published over 250 original
articles and over 60 reviews, editorials, and chapters, and has been
listed among the Best Doctors in North America for the treatment of mood
and anxiety disorders continuously since 1994. He received the NDMDA
Gerald L. Klerman Young Investigator Award and was elected as a member
of the American College of Neuropsychopharmacology (ACNP) and as a
Distinguished Fellow of the American Psychiatric Association.
Dr. Nierenberg is the Director of the
NIMH Bipolar Trials Network which is currently conducting CHOICE,
10-site nationwide comparative effectiveness trial of lithium and
quetiapine. Additionally, the Bipolar Trials Network is in the final
stages of completing LiTMUS, an effectiveness trial of low dose lithium
alone or in combination with optimized treatment. His primary interests
are treatment resistant depression, bipolar depression, and the
longitudinal course of mood disorders. Dr. Nierenberg lectures
nationally and internationally, teaches and supervises clinicians and
researchers, maintains an active clinical practice, conducts clinical
trials, and is Editor in Chief of CNS Spectrums as well as on the
editorial boards of multiple psychiatric journals.
Dost Ongür, MD,
PhD
Assistant Professor of Psychiatry, Harvard Medical School, McLean
Hospital, Belmont, MA
Dost Ongur, MD, PhD joined the faculty of Harvard Medical School in
July, 2004 after completing his psychiatry residency at the MGH/McLean
training program. Dr. Ongur’s research focuses on magnetic resonance
spectroscopy studies of glutamatergic and GABAergic abnormalities in
bipolar disorder and schizophrenia. A 2000 graduate of the Washington
University in St. Louis School of Medicine, Dr. Ongur currently is the
Clinical Director of the Psychotic Disorders Division at McLean Hospital
and has a Career Development Award from NIMH. Dr. Ongur has been elected
to Associate membership of the American College of
Neuropsychopharmacology and has authored or co-authored more than 50
scientific articles and book chapters.
Michael J. Ostacher,
MD, MPH
Assistant Professor of Psychiatry and Behavioral Sciences, Stanford
University School of Medicine
Associate Director, VA/Stanford Bipolar Research Program, VA Palo Alto
Health Care System
After graduating with Honors in the
College of Letters at Wesleyan University in Connecticut, Dr. Ostacher
received his medical degree from the Vanderbilt University School of
Medicine in Nashville, Tennessee. He trained in Adult Psychiatry at
Harvard Medical School at The Cambridge Hospital, and completed
fellowships in Public Psychiatry and Geriatric Psychiatry there. He
completed a Masters in Public Health in Health Care Management at the
Harvard University School of Public Health, and received a Masters in
Medical Sciences as part of the Scholars in Clinic Science Program at
Harvard Medical School.
Dr. Ostacher's major research interest is
bipolar disorder and comorbid substance abuse, and received a Career
Development Award from the National Institute on Alcoholism and Alcohol
Abuse (NIAAA) to study substance abuse and mood while the Associate
Medical Director of the Bipolar Clinic and Research Program at
Massachusetts General Hospital. Dr. Ostacher won National Association
for Research in Schizophrenia and Depression (NARSAD) Young Investigator
Awards in 2005 and 2009 to study cognition in patients with bipolar
disorder and substance abuse, and received a New Investigator Award in
2004 from the National Institute of Mental Health (NIMH), and is faculty
for the University of Pittsburgh/NIMH Bipolar Career Development
Institute. He was the principal investigator at MGH for BALANCE, a
multinational study of maintenance treatments for bipolar disorder at
Oxford University in the United Kingdom, and was the Site PI for the
NIMH Bipolar Trials Network at MGH. Since August 2010, he has been on
the faculty in the Department of Psychiatry and Behavioral Sciences at
the Stanford University School of Medicine, working alongside Dr. Trisha
Suppes.
Mary L. Phillips,
MD
Professor in Clinical and Translational Science
Head, Clinical and Translational Affective Neuroscience Program
Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA
Dr. Mary Phillips trained in Medicine at
the University of Cambridge, UK and in Psychiatry at the Maudsley
Hospital, London and Institute of Psychiatry, UK. She received a
research training fellowship from the Medical Research Council (UK) to
examine visual scan paths in schizophrenia. She subsequently developed a
research interest in the application of functional neuroimaging
techniques to the examination of the neural basis of emotion processing
in healthy and psychiatric populations. She has, in particular, focused
on the identification of neural correlates that underlie the symptoms of
specific abnormalities in emotion processing in individuals with mood
disorders. She became Professor of Neuroscience and Emotion and Head of
Section of Neuroscience and Emotion within the Department of Psychiatry,
Division of Psychological Medicine, Institute of Psychiatry, King’s
College, London, UK in 2003. In October, 2004, she joined the Department
of Psychiatry at the University of Pittsburgh as part-time Visiting
Professor and Director of the Functional Neuroimaging Program, moving to
become a Professor of Psychiatry in April, 2006. In 2005, Dr. Phillips
became a member of The American College of Neuropsychopharmacology, and
in 2006, was awarded the Nellie Blumenthal Investigator by the National
Alliance for Research in Schizophrenia and Depression. Since 2006, Dr.
Phillips has been Co-Director of the Brain Imaging Research Center
within Carnegie Mellon University and the University of Pittsburgh. In
January, 2008, Dr. Phillips took up a consulting adjunct position of
Professor in Clinical Affective Neuroscience in the Department of
Psychological Medicine, Cardiff University, UK. In 2009, Dr. Phillips
became Professor in Clinical and Translational Science in the University
of Pittsburgh, and now heads the Clinical and Translational Affective
Neuroscience Program in the Department of Psychiatry, University of
Pittsburgh. Dr Phillips has received research funding awards from the
Medical Research Council (UK) and the Wellcome Trust in the UK, and,
from NIMH and NARSAD in the US. Dr. Phillips is a mentor to over 30
junior investigators, has extensive national and international
collaborations, and has authored or co-authored over 170 publications.
Noreen A.
Reilly-Harrington, PhD
Director of Training and Assessment, Bipolar Trials Network
Massachusetts General Hospital & Harvard Medical School, Boston, MA
Noreen Reilly-Harrington, Ph.D. is a Founding Fellow of the Academy of
Cognitive Therapy and specializes in the cognitive-behavioral treatment
of bipolar disorder. She has co-authored several books and numerous
manuscripts on this topic. She is a graduate of the University of
Pennsylvania and Temple University and completed both her pre-doctoral
internship and post-doctoral fellowship in cognitive-behavioral therapy
at Massachusetts General Hospital and Harvard Medical School. Dr.
Reilly-Harrington served as the Clinical and Scientific Coordinator of
the Psychosocial Pathway in the NIMH Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD), the largest study of bipolar
disorder ever conducted. She has also been the Principal Investigator on
two NIMH-sponsored Small Business Innovative Research projects geared at
improving the design and reliability of multi-site psychiatric
assessment and research. Currently, Dr. Reilly-Harrington serves as the
Director of Training and Assessment for the Bipolar Trials Network and
advises the multi-site network on protocol design, assessment selection,
and training. Dr. Reilly-Harrington is also actively involved in the
teaching and provision of cognitive-behavioral treatment at the
Massachusetts General Hospital Bipolar Clinic and Research Program and
is on the faculty of Harvard Medical School. She also serves as an
affiliated faculty member for the Career Development Institute for
Bipolar Disorder.
Martha Sajatovic,
MD
Professor of Psychiatry, Case Western Reserve University School of
Medicine in Cleveland, Ohio
Dr. Sajatovic is Professor of Psychiatry
at Case Western Reserve University School of Medicine in Cleveland,
Ohio. She is a researcher, educator, and clinician who has devoted
herself to the study and treatment of traditionally hard-to treat
populations with serious mental illness. Dr. Sajatovic is Director of
Geropsychiatry at University Hospitals Case Medical Center (UHCMC) and
holds the Willard Brown Chair in Neurological Outcomes at UHCMC/Case
Western Reserve University School of Medicine.
Dr. Sajatovic’s research interests have focused on illness outcomes in
serious mental illness such as bipolar disorder and schizophrenia. Dr.
Sajatovic is a recognized expert in the areas of treatment adherence in
bipolar disorder and in late-life bipolar disorder. She also has
research interests in the psychopharmacology of psychosis and serious
mood disorders, and in mental health rating scales. Over the last two
decades, Dr. Sajatovic has been the recipient of multiple research
grants to study serious mental illness including support from the
National Institute of Mental Health (NIMH), the National Institute of
Aging (NIA), the Ohio Department of Mental Health (ODMH), the Veterans
Health Administration (VHA), a variety of Mental Health Foundations, and
Industry Sponsored clinical trials.
Dr. Sajatovic has published widely on treatments and health services
delivery among individuals with serious mental illness including
geriatric and mixed-age individuals with bipolar disorder,
schizophrenia, depression and post-traumatic stress disorder as well as
in the area of treatment adherence in bipolar disorder. She has authored
or co-authored over 100 peer-reviewed publications, and has published
over 30 book chapters or books on serious mental illness topics.
Dr. Sajatovic has been a guest lecturer at numerous academic and
community settings, both on a national and international level,
including speaking to consumer and family advocacy groups for
individuals with psychiatric illness. Dr. Sajatovic has been a recipient
of the Exemplary Psychiatrist Award bestowed by the National Alliance
for the Mentally Ill (NAMI), and was a Depression and Bipolar Support
Alliance (DBSA) 2006 Gerald Klerman Young Investigator Award winner.
Etienne Sibille,
PhD
Associate Professor of Psychiatry, University of Pittsburgh, Pittsburgh,
PA
Etienne Sibille, Ph.D., joined the faculty of the University of
Pittsburgh in 2004, after training in molecular neuropsychiatry at
Cornell and Columbia Universities. His research goals have consistently
focused on translational research aimed at identifying the cellular and
molecular bases of depression, and specifically of the mood and affect
dysregulation component of the illness. Studies in the Sibille
laboratory encompass parallel investigations in postmortem brains of
depressed and control subjects, and in rodent genetic and environmental
models. The scientific goals are to characterize the primary pathology
of depression and to assess causality relationships between identified
molecular changes or candidate neurotransmitter systems and mood
regulation.
In addition, Dr. Sibille’s laboratory has demonstrated that biological
pathways affected during aging of the human brain largely overlap with
neuropsychiatric and other neurological disease pathways and may in fact
promote diseases, together providing a compelling rationale for
investigating aging and diseases simultaneously. These latter hypotheses
are now being tested in parallel in the human postmortem brain and in
large epidemiological studies of subjects at the vigor-to-frailty
transition.
Dr. Sibille has been elected to the
membership of the American College of Neuropsychopharmacology and has
authored more than 40 scientific research articles. He is the recipient
of several NIMH grants and of a NIMH Independent Scientist Award.
Maria Silva
Family Support Partner Supervisor/Coach, High Fidelity Wraparound
Program
Children Youth and Families (CYF) and Gwen’s Girls Initiatives,
Pittsburgh, PA
Maria Silva is a Supervisor and
Credentialed Coach at Allegheny Family Network – specializing in High
Fidelity Wrap Around. Since 1996, Ms. Silva has provided peer-to-peer
crisis and emotional support to parents raising children with mental
health issues, cognitive disabilities, behavioral concerns, and
educational issues in various roles and positions. Ms. Silva formed and
served as president of the Pennsylvania Prader-Willi Syndrome
Association where her chapter has offered trainings, conferences, and
support to other families raising children with Prader-Willi Syndrome.
She serves on the National Prader-Willi Peer-to-Peer Support Network.
Ms. Silva has raised six children, three of whom have various mental
health challenges. Through her professional career and personal calling,
Ms. Silva continues to offer hope and leadership to families as they
journey towards acceptance, resiliency, and self-advocacy.
Stephen M.
Strakowski, MD
Professor and Chairman, University of Cincinnati College of Medicine,
Cincinnati, Ohio
Stephen M. Strakowski, MD, is the Dr.
Stanley and Mickey Kaplan Professor and Chairman of Psychiatry at the
University of Cincinnati College of Medicine, and the Chief of
Psychiatry at University Hospital. He is also the Director of the Center
for Imaging Research, a core human research MRI center for the
University and the Brain Imaging Center at the Lindner Center of HOPE, a
University affiliate. He also serves as the Director of Research for
University of Cincinnati Physicians. Finally, he is also Professor of
Psychology and Biomedical Engineering at UC. Dr. Strakowski graduated
summa cum laude from the University of Notre Dame with a BSE in 1984 and
alpha omega alpha from Vanderbilt University School of Medicine with an
MD in 1988. He completed his residency training at McLean
Hospital/Harvard University School of Medicine in 1992. Upon completing
residency, he moved to the University of Cincinnati as an Assistant
Professor, where he has remained and has been promoted to his current
positions. Dr. Strakowski has received numerous awards and has been
named among the Best Doctors in America for many years. He has over 200
peer-reviewed publications and over 300 chapters, published abstracts,
and solicited reviews. He serves on several editorial boards and is the
Field Editor for Neuroimaging for Bipolar Disorders.
Trisha Suppes,
MD, PhD
Director, Bipolar Disorder Research Program, VA Palo Alto Health Care
System, Palo Alto, CA
Professor, Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine, Stanford, CA
Trisha Suppes, M.D., Ph.D. joined the
faculty of Stanford University and the VA Palo Alto as Professor of
Psychiatry and Behavioral Sciences in 2008, following more than fifteen
years at the University of Texas Southwestern Medical Center. Her areas
of expertise and research include long-term treatment strategies for
bipolar disorder, treatment for bipolar II disorder, development and
implementation of treatment algorithms, treatment of bipolar depression
and use of complementary medicine for bipolar disorder. A 1987 graduate
of Dartmouth Medical School, Dr. Suppes was a member of the American
Psychiatric Association (APA) Work Group for the Practice Guidelines for
Bipolar Disorder, was chair for the Veterans Affairs, DoD and VA Bipolar
Disorder Treatment Guidelines, and is currently a member the Mood
Disorder Workgroup for the development of the Diagnostic and Statistical
Manual for Mental Disorders, version 5 (DSM-5). Additionally, Dr. Suppes
is a Distinguished Fellow with the American Psychiatric Association, a
Fellow with the American College of Neuropsychopharmacology, a member of
the Board of Councilors for the International Society for Bipolar
Disorders, an associate editor for the American Journal of Psychiatry
and a member of the Scientific Advisory Board of the Depression and
Bipolar Support Alliance. She has authored or co-authored over 185
peer-reviewed articles.
Holly A. Swartz,
MD
Associate Professor of Psychiatry, University of Pittsburgh School of
Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA
Dr. Swartz received a bachelor’s degree from Harvard University in
Cambridge, Massachusetts and her medical degree from the Albert Einstein
College of Medicine in the Bronx, New York. She completed her
psychiatric residency at Payne Whitney Clinic-New York Hospital in New
York City, and she joined the faculty of the Department of Psychiatry at
the University of Pittsburgh Medical School in 1997. She is currently an
attending psychiatrist at the Depression and Manic-Depression Prevention
Program of Western Psychiatric Institute and Clinic.
Dr. Swartz’s research is supported by the National Institute of Mental
Health (NIMH) and focuses on the development and evaluation of
psychosocial interventions for the treatment of mood disorders. She is
currently evaluating the roles of psychotherapy and pharmacotherapy in
the management of bipolar ll disorder. She is also evaluating the impact
of maternal depression treatment on offspring with psychiatric
disorders. She is the recipient of several research awards including a
2003 NCDEU New Investigator Award, the 2005 Gerald L. Klerman Young
Investigator Award from the Depression and Bipolar Support Alliance, and
the 2009 Klerman Interpersonal Psychotherapy Award from the
International Society for Interpersonal Psychotherapy. She has authored
or co-authored over 60 scientific papers and book chapters. Dr. Swartz
has presented her work at numerous local, national, and international
workshops, conferences and scientific meetings.
Mauricio Tohen,
MD, DrPH, MBA
Head of the Division of Mood and Anxiety Disorders
Aaron and Bobbie Eliott Krus Chair Endowed Professor in Psychiatry
University of Texas Health Science Center at San Antonio, TX
Dr. Mauricio Tohen graduated as a doctor of medicine from the National
University of Mexico and as a doctor of public health (epidemiology)
from Harvard University. His postdoctoral training included a residency
in psychiatry at the University of Toronto and a fellowship at McLean
Hospital, Harvard Medical School. He also obtained an MBA degree from
Indiana University Kelly School of Business.
From 1988 to 1997, he was clinical director of the Bipolar and Psychotic
Disorder Program at McLean Hospital. From 1997 to 2008 he worked at
Lilly Research Laboratories attaining the highest possible scientific
level of Distinguished Lilly Scholar. In 2009 he joined the University
of Texas Health Science Center at San Antonio as Head of the Division of
Mood and Anxiety Disorders and the Aaron and Bobbie Eliott Krus Chair
Endowed Professor in Psychiatry
He received a National Service Award in Psychiatric Epidemiology from
NIMH and Harvard University. He also received a FIRST award from NIMH,
the Pope Award from McLean Hospital, and a NARSAD Young Investigator
Award. Dr. Tohen's research, supported by grants from NIMH and the
pharmaceutical industry, has focused on the epidemiology, outcome, and
treatment of bipolar disorder.
In 2011 Dr. Tohen received the Simon Bolivar Award from the American
Psychiatric Association. He has served on the Council on Research and
the committee on Health Services Research of the American Psychiatric
Association. He has also served in the Epidemiology & Genetics and the
Clinical Centers and Special Projects Review committees at NIMH. Dr.
Tohen has over 200 publications. He has co-edited four books,
Psychiatric Epidemiology (1995, second edition 2003), Mood Disorders
Across the Life Span (1996) ). Bipolar Disorder: The Upswing In Research
and Treatment (2005) and Bipolar Psychopharmacotherapy (2006). He also
edited the book Comorbidity in Affective Disorders (1999).
Bryan K. Tolliver,
MD, PhD
Assistant Professor of Psychiatry, Medical University of South Carolina,
Charleston, SC
Bryan K. Tolliver, M.D., Ph.D. is an
Assistant Professor in the Clinical Neuroscience Division of the
Department of Psychiatry and Behavioral Sciences at the Medical
University of South Carolina. His primary clinical and research interest
is in the treatment of co-occurring bipolar disorder and substance use
disorders. After undergraduate training at the University of North
Carolina at Chapel Hill, Dr. Tolliver received a Ph.D. from the
Department of Pharmacology at the University of Kentucky in 1994 and
completed a postdoctoral fellowship in preclinical addiction research
training at the University of California, San Francisco from 1994-1999.
After receiving his medical degree from the University of Kentucky
College of Medicine in 2003, he completed psychiatry residency in 2007
and addiction psychiatry fellowship training in 2008, both at the
Medical University of South Carolina. Dr. Tolliver has received
fellowship and grant support from the National Institute of Mental
Health (NIMH), the National Institute on Drug Abuse (NIDA), and the
National Institute on Alcohol Abuse and Alcoholism (NIAAA). He is
currently funded by NIAAA to investigate medication treatment effects on
drinking, mood, and neurocognitive outcomes in individuals with
co-occurring bipolar disorder and alcohol dependence. Dr. Tolliver
presently serves on the Evidence-Based Treatment Committee of the
American Academy of Addiction Psychiatry and on the Research Committee
of the International Society for Bipolar Disorders.
Eduard Vieta, MD,
PhD
Professor of Psychiatry, University of Barcelona
Director, Bipolar Disorders Program, Hospital Clinic, Barcelona, Spain
Eduard Vieta is Professor of Psychiatry
and the Director of the Bipolar Disorders Program of the Hospital Clinic
at the University of Barcelona, in Barcelona, Spain. His research
focuses on the neurobiology, epidemiology, and treatment of bipolar
disorder. He is the current Director of the Bipolar Research Program at
the Centro de Investigación en Red de Salud Mental (CIBERSAM), funded by
the Spanish Ministry of Science and Innovation and one of the leaders of
the European Network on Bipolar Expert Centers (ENBREC). He has also
been nominated the official advisor on mood disorders research for the
EU Presidency (Hungarian Government) and sits in the Executive Committee
of the European College of Neuropsychopharmacology (ECNP). He has made
significant contributions to many of the current bipolar disorder
treatment guidelines, and with an H index of 46, has authored more than
400 original articles in peer-reviewed, top-ranking journals, 160 book
chapters and 28 complete books. He is the most cited psychiatrist in
Spain and sits on the editorial board of 18 international scientific
journals and reviews articles for more than 30 others. He recently
received the Aristotle Award and the Mogens Schou Award for excellence
in bipolar disorder research.
Adele C. Viguera,
MD, MPH
Director of Mental Health Outcomes Research, Neurological Institute,
Cleveland Clinic
Co-director of the National Pregnancy Registry for Atypical
Antipsychotics
Massachusetts General Hospital, Boston, MA
Assistant Professor of Psychiatry at the Cleveland Clinic Lerner College
of Medicine
Cleveland Clinic, Cleveland, Ohio
Dr. Adele C. Viguera, M.D., M.P.H., currently serves as co-director of
the National Pregnancy Registry for Atypical Antipsychotics and holds a
joint appointment at the Cleveland Clinic and Massachusetts General
Hospital. She is an Assistant Professor of Psychiatry at the Cleveland
Clinic Lerner College of Medicine.
Dr. Viguera received her undergraduate degree from Harvard University,
her medical degree from Dartmouth Medical School, and her Masters Degree
in Epidemiology from the Harvard School of Public Health. She completed
her Internship in Medicine from Massachusetts General Hospital,
residency training in Psychiatry at McLean Hospital, and a fellowship in
Perinatal and Reproductive Psychiatry at Massachusetts General Hospital.
She has also served as the Associate Director of the Perinatal and
Reproductive Psychiatry Clinical Research Program at Massachusetts
General Hospital since 1997.
Dr. Viguera’s research, teaching and
clinical activities focus on women’s mental health, specifically
psychiatric disorders across the female reproductive life-cycle. Her
research area is major mood disorders, in particular bipolar disorder.
She is a past recipient of several federal and private foundation
research grants including a National Institute of Mental Health (NIMH)
Mentored Patient-Oriented Career Development (K23) Award, a Harvard
Medical School Scholars in Medicine Award, and a Young Investigator
Award from the National Association of Research in Schizophrenia and
Depression (NARSAD). She is also an R01 funded principal investigator
for a collaborative, multi-site study entitled, Bipolar Disorder in
Pregnancy and the Postpartum Period: Predictors of Morbidity, sponsored
by the National Institute of Mental Health.
Dr. Viguera has published extensively in
the area of area of perinatal and reproductive psychiatry, with several
original research articles published in the American Journal of
Psychiatry. She has also been an invited speaker at numerous
international and national conferences, and served on the expert
consensus panel, convened under the aegis of the American Psychiatric
Association, for the publication of guidelines on the management of
bipolar disorder during pregnancy and the postpartum period. In addition
to these research efforts, Dr. Viguera continues to dedicate her time to
teaching and mentoring psychiatric residents, fellows, medical students,
and junior faculty.
Nora D. Volkow,
MD
Director, National Institute on Drug Abuse, National Institutes of
Health, Rockville, MD
Nora D. Volkow, M.D., became Director of
the National Institute on Drug Abuse (NIDA) at the National Institutes
of Health in May 2003. NIDA supports most of the world’s research on the
health aspects of drug abuse and addiction.
Dr. Volkow’s work has been instrumental
in demonstrating that drug addiction is a disease of the human brain. As
a research psychiatrist and scientist, Dr. Volkow pioneered the use of
brain imaging to investigate the toxic effects of drugs and their
addictive properties. Her studies have documented changes in the
dopamine system affecting the actions of frontal brain regions involved
with motivation, drive, and pleasure and the decline of brain dopamine
function with age. She has also made important contributions to the
neurobiology of obesity, ADHD, and the behavioral changes that occur
with aging.
Dr. Volkow was born in Mexico, attended
the Modern American School, and earned her medical degree from the
National University of Mexico in Mexico City, where she received the
Premio Robins award for best medical student of her generation. Her
psychiatric residency was at New York University, where she earned the
Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric
Residents in the USA.
Dr. Volkow spent most of her professional
career at the Department of Energy’s Brookhaven National Laboratory (BNL)
in Upton, New York, where she held several leadership positions
including Director of Nuclear Medicine, Chairman of the Medical
Department, and Associate Director for Life Sciences. In addition, Dr.
Volkow was a professor in the Department of Psychiatry and Associate
Dean of the Medical School at the State University of New York (SUNY)-Stony
Brook.
Dr. Volkow has published more than 440
peer-reviewed articles and more than 75 book chapters and non-peer
reviewed manuscripts, and has also edited three books on the use of
neuroimaging in studying mental and addictive disorders.
During her professional career, Dr.
Volkow has been the recipient of multiple awards, including her
selection for membership in the Institute of Medicine in the National
Academy of Sciences and the International Prize from the French
Institute of Health and Medical Research for her pioneering work in
brain imaging and addiction science. She was recently named one of Time
Magazine's “Top 100 People Who Shape our World” and was included as one
of the 20 people to watch by Newsweek magazine in its “Who’s Next in
2007” feature. She was also included in Washingtonian Magazine’s 2009
list of the “100 Most Powerful Women” and named “Innovator of the Year”
by U.S. News & World Report in 2000.
Katherine L. Wisner,
MD, MS
Professor of Psychiatry, Obstetrics/Gynecology and Reproductive
Sciences, Epidemiology and
Women’s Studies, University of Pittsburgh
Director, Women's Behavioral HealthCARE Program
Western Psychiatric Institute and Clinic of the University Pittsburgh
Medical Center, Pittsburgh, PA
Katherine L. Wisner M.D., M.S., is
Professor of Psychiatry, Obstetrics/Gynecology and Reproductive
Sciences, Epidemiology and Women’s Studies at the University of
Pittsburgh, and director of the Women's Behavioral HealthCARE program at
the Western Psychiatric Institute and Clinic (WPIC) of the University
Pittsburgh Medical Center. She also serves as an investigator at the
Magee-Womens Research Institute. Dr. Wisner obtained an M.S. in
Nutrition and her M.D. from Case Western Reserve University, followed by
a categorical pediatric internship and general and child psychiatry
residency at Children’s Hospital of Pittsburgh and WPIC. She completed
as a post-doctoral fellow in Epidemiology at the University of
Pittsburgh Graduate School of Public Health from 1985-1988 and a
fellowship in Professional Ethics at Case Western Reserve University in
1996.
Dr. Wisner's main focus is research
related to the psychiatric treatment of women of childbearing age. She
is recognized as an expert in the treatment of depression during
pregnancy and the postpartum period. She currently is the principal
investigator on several National Institute of Mental Health and
foundation-funded research projects including a large-scale postpartum
depression screening at Magee Womens Hospital, the use of antidepressant
and antimanic agents during pregnancy, novel treatments for postpartum
depression, the efficacy of bright light treatment for patients with
bipolar disorder and mental health treatment delivery within community
settings.
Dr. Wisner is board-certified in general,
child and adolescent psychiatry. Her memberships in scientific societies
include the Organization of Teratology Information Specialists (Board
member), North American Society for Psychosocial Obstetrics and
Gynecology, American College of Neuropsychopharmacology (Chair of Human
Subjects Committee) and the Marce International Society for the Study of
Childbearing-Related Psychiatric Illness (past President). Dr. Wisner is
a distinguished fellow of the American Psychiatric Association and was a
consultant for the U.S. Centers for Disease Control and Prevention’s
Safe Motherhood Initiative, the Agency for Healthcare Research and
Quality’s report on Perinatal Depression, and the Food and Drug
Administration’s pediatric subcommittee on the effects of maternal SSRI
use on newborns. Dr. Wisner completed the prestigious Executive
Leadership in Academic Medicine (ELAM) program from Drexel University.
She has authored more than 150 peer-reviewed articles and book chapters.
For relaxation, Dr. Wisner has a Morgan
horse and trains in dressage.
Lakshmi N. Yatham,
MBBS, FRCPC, MRCPsych (UK)
Professor of Psychiatry and Vice Chair for Research and International
Affairs
Department of Psychiatry at the University of British Columbia in
Vancouver, BC, Canada
Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), is Professor of
Psychiatry and Vice Chair for Research and International Affairs in the
Department of Psychiatry at the University of British Columbia in
Vancouver. His major areas of research interest include neurobiology and
treatment of bipolar disorder and major depression. Dr. Yatham has
received a number of awards during his career including the Michael
Smith Foundation Senior Scholar Award, Mogen Schou Award for
international education and advocacy on bipolar disorder and the
Canadian College of Neuropsychopharmacology Medal for his contributions.
Dr. Yatham’s work has been funded by a number of peer-reviewed funding
agencies such as the Canadian Institutes of Health Research (CIHR),
Canadian Psychiatric Research Foundation, Stanley Foundation, and
National Alliance for Research on Schizophrenia and Depression, USA. Dr.
Yatham leads a Canadian consortium on bipolar disorder, which is
currently pursuing testing of new treatments for bipolar disorder using
pragmatic and controlled trials with substantial funding from CIHR.
Dr. Yatham co-led the development of Canadian guidelines for treatment
of bipolar disorder in 1997 and his group revised the guidelines for
2005 with International Commentaries. The CANMAT guidelines are widely
used for treatment of bipolar disorder around the world as these are
updated and published every 2 years in Bipolar Disorders Journal with
the most recent update published in May 2009. He is Chair of the bipolar
group of the Canadian Network for Mood and Anxiety Treatments (CANMAT),
and is actively involved at a national and international level in
continuing medical education and public education on diagnosis and
treatment of bipolar disorder for psychiatrists, family physicians, and
the general public. Dr. Yatham was the past President of the
International Society for Bipolar Disorders. He sits on the editorial
boards of a number of journals including Bipolar Disorders, World
Journal of Biological Psychiatry, Human Psychopharmacology, Quarterly
Journal of Mental Health etc. He has published over 180 papers in
peer-reviewed international journals and presented his research work at
numerous international conferences. He has also edited a number of
journal supplements and books.
Robert H. Yolken,
MD
Ted and Vada Stanley Distinguished Professor of Developmental
Neurovirology
Johns Hopkins School of Medicine, Baltimore, MD
Dr Yolken graduated from Harvard Medical School in 1973m completed
residency in Pediatrics And Medicine at Yale New Haven Hospital and a
Fellowship at New York Hospital. He then received training in the fields
of virology and infectious diseases at the National Institutes of
Health. He joined the Department of Pediatrics at Johns Hopkins in 1979
and has remained on the faculty of Johns Hopkins since that time. Dr.
Yolken initially focused on infections of the gastrointestinal tract.
Since 1995 he has focused on infections of the central nervous system
particularly as to how they relate to psychiatric disorders such as
schizophrenia and bipolar disorder. He is the author of more than 350
publications and many book chapters. He also serves on the boards of the
Stanley Medical Research Institute and the March of Dimes.
L. Trevor Young,
MD, PhD, FRCPC
Chair, Department of Psychiatry , University of Toronto, Toronto,
Ontario, Canada
Dr. Young was appointed Chair, Department
of Psychiatry effective September 1, 2010. He received his medical
degree at the University of Manitoba. This was followed by residency
training at McGill University and the University of Toronto where he
also completed his PhD in Medical Sciences. He completed a Research
Fellowship at Johns Hopkins University. His former roles include
Physician-in-Chief, Executive Vice President Programs at the Centre for
Addiction and Mental Health, Professor and Cameron Wilson Chair in
Depression Studies in the Department of Psychiatry at the University of
Toronto, and Professor and Head, Department of Psychiatry, University of
British Columbia. He was received numerous awards including the Douglas
Utting Award for outstanding contributions in the field of mood
disorders, the Canadian College of Neuropsychopharmacology Heinz Lehmann
Award, and is a Distinguished Fellow of the American Psychiatric
Association. He has led several large clinical programs including the
Mood Disorders Program at Hamilton Psychiatric Hospital, which received
the American Psychiatric Services Gold Achievement Award. In 2009, he
was elected as a Fellow of the Canadian Academy of Health Sciences.
As an active clinician scientist, Dr.
Young’s principal research interest includes understanding the molecular
basis of bipolar disorder and its treatment, and how to apply these
findings to the clinical setting. He is widely published and well funded
by peer-reviewed granting agencies. His research is particularly focused
on understanding the processes that lead to long-term changes in brain
structure and function in patients with bipolar disorder and how these
changes can be targeted by mood stabilizing drugs.
Carlos A. Zarate,
MD
Chief, Experimental Therapeutics & Pathophysiology Branch
Section on Neurobiology and Treatment of Mood and Anxiety Disorder
Division Intramural Research Program, National Institute of Mental
Health, Bethesda, MD
Carlos A. Zarate, M.D. is Chief,
Experimental Therapeutics & Pathophysiology Branch and of the Section on
Neurobiology and Treatment of Mood and Anxiety Disorders, Division
Intramural Research Program, National Institute of Mental Health. Dr.
Zarate completed his residency training in psychiatry at the
Massachusetts Mental Health Center/Brockton VAMC division. He later
completed a fellowship in Clinical Psychopharmacology at McLean Hospital
of the Consolidated Department of Psychiatry, Harvard Medical School and
remained on staff at McLean Hospital as the Director of the Bipolar and
Psychotic Disorders Outpatient Services and Director of the New and
Experimental Clinic. From 1998 to 2000 Dr. Zarate was the Chief of the
Bipolar and Psychotic Disorders Program at the University of
Massachusetts Medical School. In 2001, he joined the Mood and Anxiety
Disorders Program at NIMH. His achievements and awards include the
Ethel-DuPont Warren Award and Livingston Awards, Consolidated Department
of Psychiatry, Harvard Medical School; Outstanding Psychiatrist Research
Award, Massachusetts Psychiatric Association; Program for Minority
Research Training in Psychiatry, APA; the National Alliance for Research
on Schizophrenia and Depression Young Investigator Award; National
Alliance for Research on Schizophrenia and Depression Independent
Investigator Award; and the National Institutes of Health Director’s
Award Scientific/Medical. Dr. Zarate has been elected to membership to
the American College of Neuropsychopharmacology. Dr. Zarate’s research
focuses on the pathophysiology and development of novel therapeutics for
treatment-resistant mood disorders as well as the study of biosignatures
of treatment response.
|
